EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells

Alexandra Calescibetta, Robert Dalton, Nicole Fortenbery, Grace Ward iD, Sean Christiansen, Xianghong Chen, Pingyan Cheng, Tiffany Razabdouski, Annelise J Glode iD, Nhan Tu, Thu Le Trinh, Jinghong Liu und 3 weitere

PLOS One · 12.03.2026 · 21 (3) · e0344471

DOI: 10.1371/journal.pone.0344471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 12.03.2026. Verfasst von Alexandra Calescibetta und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United Nations of America. Hauptthemen laut MEDLINE: Killer Cells, Natural, Interleukin-2, Thalidomide, Perforin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lenalidomide is an immunomodulatory drug approved in the treatment of autoimmune disease, inflammation, and cancer. Its impact continues to grow due to its diverse spectrum of effects hampered only by toxicities and reduced efficacy. Therefore, development of strategies that enhance function while reducing drawbacks remains a prime goal. Objective and Hypothesis The mechanisms of action of lenalidomide on the activity of natural killer cells (NK cells) remains understudied yet could be critical for the development of strategies to enhance its efficacy. These cells are critical drivers of anti-tumor immune responses which are often functionally suppressed in malignancies. NK cell and T cell survival and function is driven by the IL-2 family of cytokines (IL-2 or IL-15) and work has shown that lenalidomide potentially works by increasing the secretion of IL-2 by other lymphocytes, such as CD4 + T helper cells. Thus, we hypothesized that improving NK activity with IL-2 family of cytokines could lead to enhanced lenalidomide-induced responses of these cells.

Results

We show that lenalidomide does not affect NK cell viability but reduces their proliferation through cell cycle arrest which could be overcome by exogenous addition of IL-2 family of cytokines. Moreover, lenalidomide induced the secretion of IL-2 on isolated NK cells although it also modulated NK receptor expression, such as NKp46, trough downregulation of PI3K/AKT pathway reduction. This was overcome by exogeneous addition of IL-2 family of cytokines increasing natural cytotoxicity, through higher perforin and granzyme expression. Mechanistically, this increased gene and protein expression occurred through the activation of STAT5 by lenalidomide which was also enhanced through the exogenous addition of IL-2 family of cytokines and modulation of IL-2R subunit changes.

Conclusions

These data provide a rationale for the combination of lenalidomide with IL-2 family of cytokines to enhance the effectiveness of NK cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalInterleukin-2ThalidomidePerforinGranzymesLenalidomideHumansCell ProliferationInterleukin-15Cell Survival

Substanzen

LenalidomideInterleukin-2ThalidomidePerforinGranzymesInterleukin-15

Autor:innen und Institutionen

  • Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United Nations of America.
  • Cancer Biology PhD Program, University of South Florida and H. Lee Moffitt Cancer Center, Tampa, Florida, United Nations of America.

ORCID-Profile: Grace Ward, Annelise J Glode, Erika Adriana Eksioglu

Förderung

  • National Cancer Institute

Zitieren

APA

Calescibetta, A., Dalton, R., Fortenbery, N., Ward, G., Christiansen, S., Chen, X., Cheng, P., Razabdouski, T., Glode, A. J., Tu, N., Trinh, T. L., Liu, J., Wright, K. L., Wei, S., & Eksioglu, E. A. (2026). Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. PLOS One, 21(3), e0344471. https://doi.org/10.1371/journal.pone.0344471

Vancouver

Calescibetta A, Dalton R, Fortenbery N, Ward G, Christiansen S, Chen X, et al. Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. PLOS One. 2026;21(3):e0344471. doi:10.1371/journal.pone.0344471

BibTeX
@article{Calescibetta2026,
  author = {Calescibetta, Alexandra and Dalton, Robert and Fortenbery, Nicole and Ward, Grace and Christiansen, Sean and Chen, Xianghong and Cheng, Pingyan and Razabdouski, Tiffany and Glode, Annelise J and Tu, Nhan and Trinh, Thu Le and Liu, Jinghong and Wright, Kenneth L and Wei, Sheng and Eksioglu, Erika Adriana},
  title = {Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {e0344471},
  doi = {10.1371/journal.pone.0344471}
}
Kostenlos starten →